CD52 and B-cell chronic lymphocytic leukemia: Its associated monoclonal antibodies, anti-CD52, including alemtuzumab and analogues, are intended for treatment of multiple sclerosis and B cell chronic lymphocytic leukemia [34], with its specific expression patterns being observed in the inflammatory meta program.